BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24373609)

  • 1. A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer.
    Waqar SN; Robinson C; Bradley J; Goodgame B; Rooney M; Williams K; Gao F; Govindan R
    Clin Lung Cancer; 2014 Mar; 15(2):119-23. PubMed ID: 24373609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).
    Schild SE; Hillman SL; Tan AD; Ross HJ; McGinnis WL; Garces YA; Graham DL; Adjei AA; Jett JR;
    J Thorac Oncol; 2017 Apr; 12(4):697-703. PubMed ID: 28089762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305.
    Tada T; Chiba Y; Tsujino K; Fukuda H; Nishimura Y; Kokubo M; Negoro S; Kudoh S; Fukuoka M; Nakagawa K; Nakanishi Y
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):327-31. PubMed ID: 22079726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer.
    Takeda K; Negoro S; Kudoh S; Okishio K; Masuda N; Takada M; Tanaka M; Nakajima T; Tada T; Fukuoka M
    Br J Cancer; 1999 Mar; 79(9-10):1462-7. PubMed ID: 10188891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe pulmonary resection after chemotherapy and high-dose thoracic radiation.
    Sonett JR; Krasna MJ; Suntharalingam M; Schuetz J; Doyle LA; Lilenbaum R; Gamliel Z
    Ann Thorac Surg; 1999 Aug; 68(2):316-20. PubMed ID: 10475388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
    Tokuda Y; Takigawa N; Kozuki T; Kamei H; Bessho A; Tada A; Hotta K; Katsui K; Kanazawa S; Tanimoto M; Kiura K
    Acta Oncol; 2012 Apr; 51(4):537-40. PubMed ID: 22085375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer.
    Choy H; Schwartzberg LS; Dakhil SR; Garon EB; Gerber DE; Choksi JK; Govindan R; Peng G; Koustenis A; Treat J; Obasaju C
    J Thorac Oncol; 2013 Oct; 8(10):1308-16. PubMed ID: 23981966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer.
    Shien K; Toyooka S; Kiura K; Matsuo K; Soh J; Yamane M; Oto T; Takemoto M; Date H; Miyoshi S
    Ann Surg Oncol; 2012 Aug; 19(8):2685-92. PubMed ID: 22396006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
    Ramalingam SS; Owonikoko TK; Behera M; Subramanian J; Saba NF; Kono SA; Gal AA; Sica G; Harvey RD; Chen Z; Klass CM; Shin DM; Fu H; Sun SY; Govindan R; Khuri FR
    J Thorac Oncol; 2013 Mar; 8(3):369-72. PubMed ID: 23407561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.
    Descourt R; Vergnenegre A; Barlesi F; Lena H; Fournel P; Falchero L; Berard H; Hureaux J; Le Caer H; Chavaillon JM; Geriniere L; Monnet I; Chouabe S; Robinet G;
    J Thorac Oncol; 2011 Feb; 6(2):351-7. PubMed ID: 21164367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.
    Westover KD; Loo BW; Gerber DE; Iyengar P; Choy H; Diehn M; Hughes R; Schiller J; Dowell J; Wardak Z; Sher D; Christie A; Xie XJ; Corona I; Sharma A; Wadsworth ME; Timmerman R
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):72-81. PubMed ID: 26279026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
    Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
    J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
    Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
    Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
    Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
    J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial.
    Yao L; Xu S; Xu J; Yang C; Wang J; Sun D
    Radiat Oncol; 2015 Jan; 10():10. PubMed ID: 25572571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
    Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
    Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matched-Pair Analysis of High Dose Versus Standard Dose Definitive Chemoradiation for Locally Advanced Non-Small-Cell Lung Cancer.
    Johnson MD; Sura K; Mangona VS; Glick A; Wallace M; Ye H; Grills IS
    Clin Lung Cancer; 2017 Mar; 18(2):149-155. PubMed ID: 27426973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.